|
Jonathan Birt heads the U.S. Healthcare and Life Sciences practice. He joined FD-US in 2003 from FD’s healthcare team in London, where he was responsible for building FD’s European business. Jonathan has developed IR and PR programs for many leading international life sciences companies, including GE Healthcare, Novartis, Amersham, Smith & Nephew, GSK and Shire. Transactions experience includes Sanofi’s acquisition of Aventis, Smith & Nephew’s bid for Centerpulse, Charles River Laboratories’ acquisition of Inveresk and Shire’s acquisition of TKT. He has also worked with many smaller companies including Acambis, Aspreva Pharmaceuticals, Digene, Hooper Holmes, NicOx, Protherics, and EvotecOAI. Before joining FD, Jonathan spent 12 years as a financial journalist, including six years following the healthcare sector as the European pharmaceuticals and biotechnology correspondent at Dow Jones and then Reuters. He is the former Chief Correspondent, European Equities, at Reuters and former Chief Correspondent, UK Equities, at Dow Jones & Co. | 